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In a previous study, we showed that a novel anticancer drug, 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine (TAS106, ECyd)
increased the antitumour efficacy of X-irradiation. However, its effects on hypoxic cells in tumours remain unclarified. Here, we show
that TAS106 enhances the induction of apoptosis in X-irradiated human gastric adenocarcinoma MKN45 and MKN28 cells under
hypoxia in vitro. At the same time, the accumulation of HIF-1a observed under hypoxia was shown to be decreased to the level of
normoxia in the presence of 0.1mM TAS106. To study the function of HIF-1a protein in apoptosis of hypoxic cells, we employed an
HIF-1a reductive approach using its specific antisense oligodeoxynucleotide. The reduction of HIF-1a gene expression dramatically
enhanced X-ray-induced apoptosis in hypoxic cells. In in vivo experiments in which MKN45 cells were transplanted into severe
combined immunodeficient (SCID) mice, TAS106 (0.5mgkg
 1) suppressed HIF-1a expression and subsequently reduced the area of
the hypoxic region in the tumour and enhanced the induction of apoptosis in the hypoxic region when combined with 2Gy of
X-irradiation. These results suggest the possibility that TAS106 acts as a potent radiosensitiser through the inhibition of HIF-1a
expression and can be a useful agent against radiotherapy-resistant hypoxic cells in solid tumours.
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The ribonucleoside anticancer drug 1-(3-C-ethynyl-b-D-ribo-
pentofuranosyl)cytosine (TAS106, ECyd) shown in Figure 1A was
first synthesised in 1995 and has been developed as a novel
anticancer drug (Hattori et al, 1996). When TAS106 (ECyd) is
ingested into tumour cells, it is rapidly phosphorylated to ECyd
50-triphosphate, which has the potential to inhibit RNA synthesis
because of its inhibition of RNA polymerase, leading to cell death
(Shimamoto et al, 2002; Matsuda and Sasaki, 2004). Uridine/
cytidine kinase (UCK) is a key enzyme for the first phospho-
rylation of TAS106 to ECyd 50-monophosphate, generating
cytotoxicity. The high activity of UCK in tumour cells relative to
normal cells (Maehara et al, 1982; Koizumi et al, 2001; Matsuda
and Sasaki, 2004) gives TAS106 an advantage in specificity for
tumour therapy. In earlier studies, we have shown that both
apoptosis and loss of clonogenic survival are induced through the
abrogation of arrest at the G2/M phase in X-irradiated human
(MKN45 and MKN28) and murine (Colon26) tumour cells, as well
as Chinese hamster V79 normal cells, when X-irradiation is
combined with TAS106 treatment in vitro (Inanami et al, 2004;
Iizuka et al, 2005). The radiosensitising effects of TAS106 were also
seen in colon26-transplanted tumours and MKN45 xenografts in
vivo (Yasui et al, 2007). Interestingly, our previous study showed
that repetitive treatments (three times at 2-day intervals) with the
combination of X-irradiation and TAS106 induced tumour
remission in half of the mice, whereas the treatment with
X-irradiation alone or TAS106 alone showed only slight retarda-
tion of tumour growth without tumour remission. This result
suggested the possibility that TAS106 radiosensitised hypoxic cells
in addition to normoxic cells.
Hypoxia-inducible factor 1 (HIF-1) is a key mediator expressed
in many cell types in response to oxygen deprivation. HIF-1a,a n
oxygen-sensitive HIF-1 subunit, plays an important role in
protecting solid tumours against radio- and chemotherapy by
promoting angiogenesis, increasing glucose metabolism and
modulating apoptosis. In fact, Koukourakis et al and Vergis et al
(Vergis et al, 2008) demonstrated that the overexpression of HIF-1a
in squamous cell head-and-neck cancer and prostate cancer was
associated with incomplete responses to surgery, chemotherapy,
radiotherapy and chemoradiotherapy and with poor overall
survival in clinical studies (Koukourakis et al, 2002). HIF-1a
generally inhibits the induction of apoptosis by anticancer agents
(Semenza, 2003; Kilic et al, 2007). It has been shown that HIF-1a
exerts its antiapoptotic function by transcriptional activation of
antiapoptotic proteins, that is, the Bcl-2 family and inhibitors of
apoptosis (IAPs), such as survivin (Dong et al, 2003; Peng et al,
2006). In our recent studies, the inhibition of survivin expression
by TAS106 was thought to mainly contribute to the radio-
sensitisation of apoptosis and the suppression of tumour growth
in vitro and in vivo (Inanami et al, 2004; Yasui et al, 2007). Thus, it
is possible to hypothesise that TAS106 controls HIF-1a expression
and results in the suppression of antiapoptotic proteins, that is, its
downstream transactivating factors.
To confirm the hypothesis described above, we examined the
effects of TAS106 on X-irradiated tumour cells under hypoxia both
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Figure 1 1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine (TAS106, ECyd) enhances X-ray-induced apoptosis in MKN45 and MKN28 cells under
normoxia and hypoxia. (A) The chemical structure of TAS106. (B) MKN45 (a) and MKN28 cells (b) treated with TAS106 (0.1 and 1.0mM for MKN45 and
MKN28, respectively) and/or 20Gy of X-irradiation were incubated for the indicated times under either normoxia or hypoxia. Apoptotic cells (%) were
measured by fluorescence microscopy of cells stained with propidium iodide. Data are expressed as mean±s.e. for three experiments. *Po0.05 vs control,
**Po0.01 vs control. (C) Cell cycle analysis of MKN45 cells treated with TAS106 and/or X-irradiation. After incubation under either normoxia or hypoxia
for 48h, cells were collected, fixed and stained with propidium iodide. The DNA content was measured by flow cytometry, and then the percentages of cell
populations in the sub-G1 fractions of total cells were scored as mean±s.e. (D) Effects of X-irradiation and TAS106 treatment on the activation of caspase-3
in MKN45 cells. Tumour cells were collected at 48h after each treatment. Arrows indicate the activated p19 and p17 fragments of casapse-3. Quantification
of band of p17 fragments of casapse-3 was performed using Image J analysis normalised to actin.
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1a expression.
MATERIALS AND METHODS
Materials
1-(3-C-ethynyl-b-D-ribo-pentofuranosyl)cytosine (TAS106) was
synthesised as described elsewhere (Hattori et al, 1996). Ultrapure
nitrogen gas (99.999%) was obtained from Air Water Technical
Supply (Ishikari, Japan).
Cell culture
Cells of human gastric adenocarcinoma cell lines MKN45 (TP53
wild-type) and MKN28 (TP53 mutation) were grown in RPMI 1640
medium (Gibco-BRL/Invitrogen, Carlsbad, CA, USA) supplemen-
ted with 10% fetal bovine serum (Filtron, Brooklyn, Australia) at
371Ci n5 %C O 2/95% air.
Cell incubation, X-irradiation and drug treatment in vitro
Tumour cells attached to a 6-cm plastic dish were treated with
TAS106 at the concentrations of 0.1 and 1.0mM for MKN45 and
MKN28 cells, respectively, 1h before hypoxic incubation. The
hypoxic condition of tumour cells in the dish (oxygen concentra-
tion o 20mmHg) was achieved by placing it in a gas-exchangeable
chamber and continuously passing 95% N2/5% CO2 for 25min on
ice. The cells were then exposed to 20Gy of X-rays while
maintaining the gas flow. X-irradiation was performed with a
Shimadzu PANTAK HF-350 X-ray generator (1.0mm Al filter,
200kVp, 20mA, Shimadzu, Kyoto, Japan). After X-irradiation, the
chamber was tightly closed and incubated at 371C for the indicated
periods. Cells under normoxia were also incubated for 25min on
ice and then exposed to X-rays. Hypoxia was also induced
chemically by treating cells with 100mM CoCl2 for 12h.
RNAi to knockdown UCK2 gene in MKN45 cells
Annealed double-stranded siRNA (Stealth Select RNAi, Invitrogen,
Carlsbad, CA, USA) for the UCK2 gene as the follows: sense strand
5UAGCCGUUGAGACAGCCAUUGGUCU3 and antisense strand
5AGACCAAUGGCUGUCAACGGCU3. Transfection of MKN45
cells with the siRNA was performed using Lipofectaminet 2000
according to the manufacturer’s instructions. As a negative control
for the siRNA treatment, medium GC Stealth RNAi negative
control duplex (MedGC, Invitrogen) was used.
HIF-1a antisense oligonucleotide treatment of tumour cells
An HIF-1a antisense phosphorothioate oligodeoxynucleotide (AS-
HIF-1a-ODN) and a scramble control (Srb-ODN) were synthesised
by Sigma Genosys (Ishikari, Japan) according to published
sequences (antisense sequence: 50-GCCGGCGCCCTCCAT-30;
scramble sequence: 50-ATGGAGGGCGCCGGC-30; Zhang et al,
2004a). MKN45 cells were exposed to either Srb-ODN or AS-
HIF-1a-ODN premixed with lipofectaminet 2000. To assess the
transfection efficiency, the 50 ends of the oligonucleotides were
conjugated to fluorescein-isothiocyanate (FITC). FITC-labeled
oligonucleotides were transfected into MKN45 cells in the same
conditions as above, and then the transfection efficiency was
assessed by counting fluorescent cells.
Fluorescence microscopic and flow cytometric
observations of apoptotic cells
The detection of apoptotic cells was performed as described
previously (Inanami et al, 2004). In brief, cells incubated for the
indicated times after X-irradiation were collected by centrifuga-
tion. For fluorescence microscopy, cells fixed with 1% glutaralde-
hyde were stained with 40mgml
 1 propidium iodide (SIGMA
Chemical Company, St Louis, MO, USA). Fluorescence micro-
scopic observation was performed using an Olympus BX50
microscope (Olympus, Tokyo, Japan). The fraction of apoptotic
cells was calculated as the percentage of apoptotic cells relative to
the total cells observed microscopically. Three independent
experiments were performed.
For flow cytometric analysis, tumour cells were collected at 48h
after X-irradiation and fixed with 70% ethanol. After being reacted
with RNase A (Roche Diagnostics, Mannheim, Germany) for
30min, the cells were stained with 50mgml
 1 propidium iodide.
The DNA content in 10000 cells was analysed using an EPICS
ALTRA flow cytometer (BECKMAN COULTER, Fullerton, CA,
USA).
Clonogenic survival assay
The surviving fraction in MKN45 and MKN28 cells, which
consisted of adherent cells and floating cells was assayed by using
the plasma clot technique with platelet-poor human plasma
according to the method described by Kashiwakura et al
(Kashiwakura et al, 2002). In brief, the cells incubated with or
without TAS106 for 24h after X-irradiation were collected by
trypsinization. Proper number (100–20000) of tumour cells with
10% human platelet-poor AB plasma, the growth factor(s),
penicillin (100Uml
 1), streptomycin (100mgml
 1), sodium pyr-
uvate (1mM), MEM vitamins (1%), MEM non-essential amino
acids (1%), thioglycerol (10mM), L-asparagine (2mgml
 1), CaCl2
(74mgml
 1) and 0.2% bovine serum albumin in Iscove’s modified
Dulbecco’s medium (Invitrogen) were plated in 24-well culture
plates and incubated at 371Ci n5 %C O 2/95% air for 14 days
(MKN45) and 10 days (MKN28). Under a microscope, colonies
containing more than 50 cells were scored as surviving cells and
the surviving fraction at each dose was calculated with respect to
the plating efficiency of the non-irradiated control. The means of
surviving fractions from three experiments were plotted to dose–
response curves.
SDS–PAGE and immunoblotting
Cells were collected at the indicated periods after X-irradiation and
lysed in lysis buffer (25mM Tris-HCl, pH 7.4; 300mM NaCl; 10%
glycerol; 3mM EDTA; 1mM MgCl2;5 0 m M b-glycerophosphate;
25mM NaF; 1% Triton X-100 and protease inhibitor cocktail).
Immunoblot analysis was performed as previously described
(Iizuka et al, 2005). The following antibodies were used: anti-
HIF-1a (BD Transduction Laboratories, San Diego, CA, USA),
anticaspase-3 (8G10; Cell Signaling Technology, Beverly, MA,
USA), anti-UCK2 (ab37886; Abcam Inc., Cambridge, MA, USA),
anti-cIAP2 (58C7; Cell Signaling Technology), antisurvivin (Alpha
Diagnostic, San Antonio, TX, USA), anti-VEGF (Lab Vision Corp.,
Fremont, CA, USA) and antiactin (Santa Cruz Biotechnology). The
bands were quantified by Image J software (National Institutes of
Health, Bethesda, MD, USA).
Semiquantitative reverse transcription–PCR (RT–PCR)
Total RNA was extracted and purified with an RNeasy Mini kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. The specific primer sequences were as follows: for
HIF-1a,5 0CCCCAGATTCAGGATCAGGATCAGACA30 and 50CCAT
CATGTTCCATTTTTCGC30; for UCK2,5 0GCGAACCATGGCCGG
GGACAGCGAG30 and 50ACAGTATGTACAGATGAGCAGTGCC30;
for GAPDH,5 0GAAGGTGAAGGTCGGAGTC30 and 50GAAGATG
GTGATGGGATTTC30. One microgram of RNA was reverse
transcribed using the Reverse Transcription System (Promega
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sCorporation, Madison, WI, USA) and amplification reactions were
performed using GoTaqt DNA Polymerase (Promega). The PCR
protocol was as follows: initial denaturation at 951C for 2min,
followed by 25 cycles at 951C for 1min, annealing at 531C (HIF-1a)
or 601C (UCK2 and GAPDH) for 1min and extension at 721C for
1min. The final extension was performed by an incubation step at
721C for 5min. The PCR products were subjected to electro-
phoresis in agarose gel and visualised with ethidium bromide.
Animals and tumour models
C.B-17/Icr. SCID Jcl mice aged 6 weeks were purchased from Japan
CLEA (Tokyo, Japan). MKN45 cells were subcutaneously injected
into the footpad of the right hind leg (5 10
6 cells per animal).
This study was conducted according to the established guide-
lines of the ‘Law for The Care and Welfare of Animals in Japan’
and approved by the Animal Experiment Committee of the
Graduate School of Veterinary Medicine, Hokkaido University
(approval no. 8092).
Drug treatment and X-irradiation in vivo
When the tumour reached a size of 350mm
3, TAS106 administra-
tion and/or X-irradiation were performed only once. Animals were
randomised into four groups: (1) no treatment, (2) X-irradiation
(2Gy) alone, (3) TAS106 administration alone and (4) TAS106
administration for 3h followed by X-irradiation (2Gy). TAS106
was i.p. injected into mice at the amount of 0.5mgkg
 1.
Transplanted tumours were irradiated with a Shimadzu PANTAK
HF-350 X-ray generator at a dose rate of 0.8Gymin
 1.
Immunohistochemical analysis of hypoxic regions and
HIF-1a
For the analysis of hypoxic regions, mice were treated with TAS106
administration and/or X-irradiation when the tumour reached a
size of 350mm
3. The sizes of the treated tumours were monitored
every day, and mice were sequentially killed when the tumour size
reached 700mm
3. To visualise tumour hypoxia, mice were killed
90min after i.p. injection of 60mgkg
 1 pimonidazole hydro-
chloride (Hypoxyprobet-1 Kit; Chemicon International Inc.,
Temecula, CA, USA). Tumour tissues excised from mice were
fixed in 4% buffered formaldehyde, embedded in paraffin and
sectioned 5-mm thick. The staining procedure for tumour hypoxia
was according to the instructions of the Hypoxyprobet-1 kit.
For HIF-1a immunostaining, the tumours were excised at 2 days
after X-irradiation and/or TAS106 administration. Antigen retrie-
val was performed by pressure heating for 3min in 0.01M citrate
buffer (pH 6.0). After quenching endogenous peroxidase, sections
were incubated with an anti-HIF-1a antibody (NB100-654; Novus
Biologicals, Littleton, CO, USA) diluted at 1:1000 overnight at 41C.
Then the slides were reacted with EnVisionþ System-HRP
labelled antirabbit polymer (K4002, Dako Cytomation, Kyoto,
Japan). Immunoreactivity was visualised by incubation with DAB.
Each stained slide was lightly counterstained with hematoxylin.
The sections were analysed under an Olympus BX50 microscope.
Immunofluorescent double staining for hypoxic cells and
apoptotic cells
Tumour tissues excised from the mice at 2 days after X-irradiation
and/or TAS106 administration were fixed with 4% paraformalde-
hyde, frozen using ultracold hexane and sectioned 8-mm thick.
After blocking non-specific binding sites, the slides were reacted
with the appropriate dilution of hypoxyprobet-1 MAb1 (1:500)
and rabbit anticleaved caspase-3 (Asp175; Cell Signaling Technol-
ogy; 1:1000) overnight at 41C. The sections were incubated with
Alexa Fluor 488 antimouse and Alexa Fluor 546 antirabbit
secondary antibodies (Molecular Probes, Eugene, OR, USA). Then
they were mounted on Prolong Gold antifade reagent with DAPI
(Molecular Probes). Fluorescence microscopic observation was
performed using an Olympus BX50 microscope with reflected light
fluorescence.
Scoring of stained sections
The hypoxic area was estimated by quantifying the ratio of the
pimonidazole-positive area vs the total area of the slice after
choosing a threshold using Scion Image software. Quantitative
analysis for HIF-1a was performed by calculating the ratio of
positively stained cells vs all tumour cells except for necrotic
regions in five random fields at  400 magnification. These
quantifications were performed on at least three different
xenografts in each treatment group.
Statistical analysis
All results were expressed as the mean±s.e. The variance ratio was
estimated by the F-test and differences in means of groups were
determined by Student’s t-test or Welch’s t-test. The minimum
level of significance was set at Po0.05.
RESULTS
TAS106 enhanced radiation-induced apoptosis under
hypoxia as well as normoxia in a UCK2-dependent manner
in tumour cells
Figure 1B (a) shows the effects of the combination of X-irradiation
(20Gy) and TAS106 (0.1mM) on apoptotic induction in MKN45
cells under normoxia and hypoxia. When MKN45 cells were
treated with X-irradiation under normoxia or hypoxia, apoptotic
induction was not observed until 48h. Treatment of cells with
TAS106 alone induced significant increases of apoptosis at 48h
under normoxia and at 36 and 48h under hypoxia. However, the
combined treatment with X-irradiation and TAS106 under
normoxia significantly enhanced apoptosis in MKN45 cells from
24h and 27.0±3.8% of cells were apoptotic at 36h, similar to an
erlier report (Inanami et al, 2004). A significant increase of
apoptotic cells was also observed under hypoxia, although the
apoptotic induction was less than that under normoxia
(18.9±3.5% at 36h).
Figure 1B (b) shows the effect of the combination of
X-irradiation and TAS106 on apoptotic induction in MKN28 cells.
Treatment of 0.1mM TAS106 could not enhance X-ray-induced
apoptosis in MKN28 cells (data not shown), suggesting that
MKN28 cells with TP53 mutation were more resistant to apoptotic
induction by X-irradiation and TAS106 than MKN45 cells with
wild-type TP53. Thus, 1.0mM was used as the dose of TAS106.
TAS106 at this dose induced 20% apoptosis at 36h under both
normoxia and hypoxia. However, enhanced induction of apoptosis
by combined treatment was observed compared to each treat-
ment alone.
To study the relationship between the radiation-induced cell
cycle checkpoint and the induction of apoptosis by TAS106, flow
cytometric analysis was performed (Figure 1C). When MKN45 cells
were exposed to 20Gy of X-rays and incubated for 48h under
either normoxia or hypoxia, the flow cytometric profile showed a
marked increase in the G2/M fraction but not in the sub-G1
fraction, suggesting the occurrence of radiation-induced G2/M
arrest without apoptosis. In addition, the treatment of cells with
TAS106 alone induced the accumulation of the G1 fraction, but not
an increase in the sub-G1 fraction. However, the combination of
X-irradiation and TAS106 resulted in a decrease in the G2/M
fraction and an increase in the sub-G1 fraction (sub-G1 fraction;
10.4–25.5% under normoxia and 10.2–16.7% under hypoxia).
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fraction by TAS106 were also observed in irradiated MKN28 cells
(data not shown). These results proved that TAS106 enhanced
radiation-induced apoptosis under both normoxia and hypoxia
regardless of the difference in the TP53 status.
As TAS106 was reported to enhance caspase-dependent
apoptosis in X-irradiated tumour cells under normoxia (Inanami
et al, 2004), we examined whether activation of caspase-3 was also
induced by the combined treatment even under hypoxia. As shown
in Figure 1D, immunoblot analysis revealed that X-irradiation
combined with TAS106 treatment induced the expression of
cleaved caspase-3 (p19 and p17, active forms of caspase-3), in
MKN45 cells under normoxia and hypoxia. When tumour cells
were treated with TAS106 alone or X-irradiation with TAS106
under hypoxia, the activation of caspase-3 was weaker than that
under normoxia, suggesting that hypoxic cells were resistant to
caspase-mediated apoptosis.
It has been reported that UCK2 is responsible for the
phosphorylation of 30-ethynyl nucleosides, including TAS106
(Murata et al, 2004), and this phosphorylation is essential for
inhibition of RNA polymerase. Therefore, to determine the
involvement of UCK2 in TAS106-induced apoptosis, we investi-
gated whether TAS106 could enhance radiation-induced apoptosis
in cells silenced UCK2 gene by RNAi. UCK2 knockdown led to a
reduction not only in UCK2 mRNA levels but also protein levels
(Figure 2A). Silencing of UCK2 prevented the apoptotic induction
by TAS106/X-irradiation treatment significantly compared to
mock-transfected and MedGC-transfected cells (Figure 2B).
Effects of TAS106 on cell survival examined by clonogenic
ability
We next examined a colony formation assay, which integrates
multiple forms of cell death, such as apoptosis, necrosis and
mitotic catastrophe, and hence gives overall cell killing that is
correlated to tumour response in vivo. The survival curves in
MKN45 cells exposed to X-rays under normoxia or hypoxia are
shown in Figure 3A. In MKN45 cells without TAS106, the
clonogenic ability in the cells exposed to X-rays under normoxia
(10% survival; D10¼2.5Gy) was lower than that under hypoxia
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Figure 2 The enhancement of radiation-induced apoptosis by TAS106 is abrogated by UCK2 knockdown in MKN45 cells. (A) Semiconfluent MKN45
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fluorescence microscopy of cells stained with propidium iodide. Data are expressed as mean±s.e. for three experiments. **Po0.01 vs mock control.
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expressed as means±s.e. for three experiments.
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s(D10¼3.7Gy). The treatment with 0.1mM TAS106 significantly
enhanced the loss of clonogenic ability of MKN45 cells exposed to
X-rays under normoxia and hypoxia (D10¼1.75Gy in normo-
xiaþTAS106 and D10¼2.75Gy in hypoxiaþTAS106). Further-
more, the clonogenic ability of MKN28 cells was also examined. As
shown in Figure 3B, clonogenic abilities in MKN28 cells exposed to
X-rays without TAS106 under normoxia (D10¼8.4Gy) and under
hypoxia (D10¼10.9Gy) were significantly higher than those of
MKN45 cells, respectively. This observation suggested that
mutation of TP53 made MKN28 cells more resistant to
X-irradiation. The treatment with 1.0mM TAS106 significantly
enhanced the loss of clonogenic ability of MKN28 cells exposed to
X-rays under normoxia and hypoxia (D10¼5.1Gy in normo-
xiaþTAS106 and D10¼6.9Gy in hypoxiaþTAS106), respectively.
Effects of TAS106 on the expression of hypoxia-induced
proteins related to apoptosis
To gain insight into the modulation of apoptotic resistance in
response to hypoxia in MKN45 cells, we next analysed the
expression of IAP family proteins under hypoxia. As shown in
Figure 4A, the expression of survivin and cIAP2 was increased
under hypoxia and their upregulation reached the maximum level
in MKN45 cells 24h after hypoxic exposure. Furthermore,
Figure 4B shows that X-irradiation did not affect survivin and
cIAP2 expression, whereas 0.1mM TAS106 abrogated the upregula-
tion of these antiapoptotic proteins under both normoxia and
hypoxia.
Effects of TAS106 on HIF-1a and VEGF expression in
MKN45 cells under hypoxia
As hypoxia in solid tumours is a potent inducer of cell survival and
angiogenesis through the upregulation of the HIF-1a-VEGF
pathway, we investigated the effects of TAS106 on these hypoxia-
related signalling molecules in MKN45 cells. As shown in
Figure 4C, the hypoxic condition significantly increased the
expression of HIF-1a up to 8.9-fold, whereas TAS106 treatment
for 48h completely inhibited its upregulation. The VEGF protein
was constitutively expressed in MKN45 cells under both normoxia
and hypoxia and was not changed by X-irradiation. However, its
expression was markedly suppressed by treatment with TAS106
alone or X-irradiation with TAS106. These data clearly showed that
TAS106 interfered with the upregulation of the HIF-1a-VEGF
pathway under hypoxia.
HIF-1a downregulation by TAS106 is largely dependent on
transcriptional inhibition
On the basis of its inhibitory effect on RNA polymerase, TAS106 is
known to regulate the expression of its target proteins at the
transcriptional level (Maehara et al, 1982; Hattori et al, 1996;
Matsuda and Sasaki, 2004). In this study, we examined the effect of
TAS106 on the mRNA expression of HIF-1a using semiquantitative
RT–PCR. As shown in Figure 5A, hypoxic exposure for 36h
increased the mRNA expression of HIF-1a moderately; however,
TAS106 treatment with or without X-irradiation obviously
inhibited the mRNA expression of HIF-1a.
In addition, we compared the effects of TAS106, actinomycin D
as an inhibitor of transcription and cycloheximide as a protein
synthesis inhibitor on the expression of hypoxia- or CoCl2-induced
HIF-1a. After MKN45 cells were exposed to hypoxia or CoCl2 in
the presence of these agents for 12h, cell lysates from tumour cells
were used for immunoblot analysis. As shown in Figure 5B, 0.1mM
TAS106 and 25ngml
 1 actinomycin D had moderate inhibitory
activities against the HIF-1a expression induced by both hypoxia
and CoCl2, whereas 10mgml
 1 cycloheximide inhibited the
expression of HIF-1a protein completely. Similar results were
obtained from an experiment on HIF-1a overexpression using
protease inhibitors, such as ALLN and MG132 (data not shown).
Apoptotic induction by HIF-1a antisense oligonucleotide
treatment in MKN45 cells under hypoxia
To confirm the role of HIF-1a protein in the apoptotic induction of
MKN45 cells under hypoxia, we tried the HIF-1a reductive
approach using its specific antisense ODN. First, to determine
whether treatment with the antisense HIF-1a ODN (AS-HIF-1a-
ODN) suppressed the expression of HIF-1a, MKN45 cells were
transfected with AS-HIF-1a-ODN for 24h, followed by incubation
for 4h under hypoxia. Figure 6A shows that hypoxia-induced HIF-
1a expression was completely abolished by AS-HIF-1a-ODN.
Transfection efficiency determined using FITC-labelled oligonu-
cleotides was approximately 40–50% at 24h after transfection for
each ODN.
We next examined whether the reduction of HIF-1a affected
apoptotic cell death of hypoxic cells. MKN45 cells were treated
with either Srb-ODN or AS-HIF-1a-ODN and then cultured under
hypoxia for an additional 48h. Figure 6B shows fluorescence
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Figure 4 Immunoblots of the expression of survivin, cIAP2, HIF-1a and
VEGF. (A) The time course of survivin and cIAP2 expression in MKN45
cells incubated under hypoxia for the indicated times. (B) Effects of
TAS106 on the expression of survivin and cIAP2 under normoxia and
hypoxia. MKN45 cells treated with 20Gy of X-irradiation and/or 0.1mM
TAS106 were incubated for 24h. (C) Effects of TAS106 on the expression
of HIF-1a and VEGF in MKN45 cells under normoxia and hypoxia. Tumour
cells were incubated for 48h after each treatment. Quantification of bands
of survivin, cIAP2, HIF-1a and VEGF were performed using Image J analysis
normalised to actin.
TAS106 radiosensitises tumour cells through HIF-1a inhibition
H Yasui et al
1447
British Journal of Cancer (2008) 99(9), 1442–1452 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
smicroscopic observation of the morphological changes in nuclei,
including DNA fragmentation and chromatin condensation.
Quantitative measurements of apoptotic induction revealed that
the transfection of Srb-ODN did not increase the percentage
of apoptotic MKN45 cells (2.4±0.1%) as compared with the
mock-transfected control (2.2±0.4%; Figure 6C), whereas
the transfection of AS-HIF-1a-ODN led to a significant increase
in the induction of apoptotic cells (23.8±3.7%). Furthermore,
combined treatment with AS-HIF-1a-ODN transfection and
X-irradiation induced a marked increase in apoptosis
(42.6±2.7%). These results proved that HIF-1a protected
MKN45 cells against hypoxia-induced apoptosis and that the
reduction of HIF-1a resulted in enhanced induction of X-ray-
induced apoptosis in hypoxic cells.
Reduction of the hypoxic area by combined treatment with
X-irradiation and TAS106 in MKN45 xenograft
In an erlier report (Yasui et al, 2007), we examined the in vivo
antitumour efficacy of X-irradiation combined with TAS106
administration against two types of transplanted tumours (murine
Colon26 and human MKN45 tumours). When 2Gy of X-irradiation
and low doses of TAS106 (0.1 and 0.5mgkg
 1 for colon26 and
MKN45 tumours, respectively) were combined, significant inhibi-
tion of tumour growth was observed in both types of tumour
compared with mice treated with X-irradiation and TAS106 alone.
In this study, we first examined the growth delays of MKN45
xenografts treated with 2Gy of X-irradiation and/or 0.5mgkg
 1
CoCl2 (12 h) Hypoxia (12 h) Normoxia (12 h)
Control
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Figure 5 TAS106 suppressed the HIF-1a expression through its
inhibitory effect on RNA synthesis in MKN45 cells. (A) MKN45 cells
treated with 20Gy of X-irradiation and/or 0.1mM TAS106 were incubated
for 36h under either normoxia or hypoxia, after which total mRNA was
isolated and the expression of HIF-1a mRNA was analysed using RT–PCR.
(B) After pretreatment with either 0.1mM TAS106, 25ngml
 1 actinomycin
Do r1 0 mgml
 1 cycloheximide for 1h, MKN45 cells were exposed to
hypoxia or 100mM CoCl2 for 12h in the presence of each drug. Cell lysates
were prepared and subjected to immunoblot analysis to examine HIF-1a
protein expression.
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Figure 6 Effects of hypoxia and X-irradiation on apoptotic induction in
MKN45 cells treated with an antisense HIF-1a oligodeoxynucleotide. (A)
Hypoxia-induced HIF-1a expression was attenuated by an antisense HIF-1a
oligodeoxynucleotide. Semiconfluent MKN45 cells were transfected with a
scramble oligodeoxynucleotide (Srb-ODN; S) or antisense HIF-1a
oligodeoxynucleotide (AS-HIF-1a-ODN; AS) for 24h, followed by
exposure to hypoxia for 3h. To examine the transfection efficiency of
Srb-ODN and AS-HIF-1a-ODN, FITC-labelled oligodeoxynucleotides
were transfected as above, and the percentage of FITC-positive cells was
measured by fluorescence microscopy. (B) Fluorescence microscopic
observation of morphological changes in nuclei of cells treated with Srb-
ODN alone, Srb-ODN and X-irradiation, AS-HIF-1a-ODN alone or AS-
HIF-1a-ODN and X-irradiation. (C) Apoptotic induction in MKN45 cells
under hypoxia treated with AS-HIF-1a-ODN and X-irradiation. After
transfection with Srb-ODN or AS-HIF-1a-ODN followed by X-irradiation,
MKN45 cells were incubated under hypoxia for 48h. Apoptotic cells (%)
were measured by fluorescence microscopy of cells stained with propidium
iodide. Data are expressed as mean±s.e. for three experiments. **Po0.01
vs control.
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sTAS106. The period it took for tumour volume to reach 700mm
3
from 350mm
3 was 8.8±0.9 days in the control group (Figure 7A).
With 2Gy of X-irradiation and 0.5mgkg
 1 TAS106, the time was
delayed 3.2 and 2.0 days, respectively, whereas their combination
delayed it 8.0 days. Next, to examine the effects of X-irradiation
and/or TAS106 treatment on tumour hypoxia, the changes in the
extents of the hypoxic areas in MKN45 xenografts were assessed by
immunohistochemical analysis of the hypoxic marker pimonida-
zole. As shown in Figure 7A, obvious reduction of the hypoxic
areas, that is, the pimonidazole-positive regions, were observed in
tumours treated with the combination of X-irradiation and
TAS106. The proportions of the hypoxic areas to the whole
tumour regions were scored as 14.2±1.7% (control), 15.4±0.8%
(X-irradiation alone) and 12.7±1.3% (TAS106 alone), indicating
that a single treatment with TAS106 reduced the tumour hypoxic
area moderately but not significantly (P40.05; Figure 7B).
However, in the case of the combination of X-irradiation and
TAS106, the proportion of the hypoxic area significantly
decreased to 9.1±1.1% compared with the control or X-irradiation
alone (Po0.05). This result suggested that the combined
treatment with X-irradiation and TAS106 significantly reduced
the hypoxic area.
Suppression of HIF-1a expression by TAS106 treatment
in vivo
To examine the effect of TAS106 on the expression of HIF-1a
protein in vivo, we performed immunohistochemical analysis of
HIF-1a (Figure 8A). Quantitative data showed that X-irradiation
(2Gy) alone had little effect on HIF-1a expression (40.0±2.4%)
compared with the control (38.1±4.1%), but it was significantly
suppressed to 15.2±1.3 and 15.1±2.6% in the tumours treated
with TAS106 alone and the combination of X-irradiation and
TAS106, respectively (Figure 8B). These results paralleled those
shown in Figure 4C, suggesting that TAS106 also inhibited HIF-1a
expression in MKN45 cells in vivo.
Induction of apoptosis in hypoxic area by combined
treatment with X-irradiation and TAS106 in MKN45
xenograft
To investigate whether the combination of X-irradiation and
TAS106 induced apoptosis in the hypoxic area, we conducted
double-immunofluorescent staining for pimonidazole and cleaved
casapse-3 using frozen tumour tissues excised 2 days after
X-irradiation and/or TAS106 administration. Apoptotic cells were
also observed in the DAPI-negative area corresponding to the
necrotic region (Figure 9). In the control group and treatment
group with either X-irradiation or TAS106 alone, few apoptotic
cells were observed, among the pimonidazole-binding hypoxic
cells. However, when tumours were treated with X-irradiation and
TAS106, an obvious increase of apoptotic cells was detected in the
hypoxic area.
DISCUSSION
We have previously shown that a wide-range inhibitor of RNA
synthesis, TAS106, enhances X-ray-induced cell death regardless of
the difference in TP53 status in vitro and in vivo (Inanami et al,
2004). The downregulation of X-ray-induced expression of survivin,
a key molecule related to tumour survival and abrogation of the G2/
M checkpoint because of the attenuation of CDC2-cyclin B1 kinase
activity by TAS106 are responsible for this combined effect.
Furthermore, we also demonstrated that low doses of TAS106 could
potentiate the antitumour efficacy of X-irradiation with 2Gy in both
murine colon26 and human MKN45-transplanted tumours (Yasui
et al, 2007). In particular, it was remarkable that repetitive treatments
with the combination of X-irradiation and TAS106 induced tumour
remission in half of the mice. On the basis of the biological activities
of TAS106 and the tumour remission caused by the repetitive
treatments, it is possible to assume that TAS106 also radiosensitises
hypoxic cells in tumours.
Hypoxia is a common phenomenon in solid tumours because
impaired vascular function results in an inadequate blood supply.
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Figure 7 Effects of the combination of TAS106 (0.5mgkg
 1) and X-irradiation (2Gy) on tumour hypoxia in MKN45 xenografts. When the tumour
reached a size of 350mm
3, mice were treated with TAS106 administration and/or X-irradiation. The sizes of treated tumours were monitored every day,
and then tumours were sequentially excised from mice when their sizes reached 700mm
3.( A) Typical photographs of MKN45 xenografts immunostained
for pimonidazole. The number of days noted in each photograph shows the time required for tumour growth from 350 to 700mm
3.( B) The proportions of
hypoxic areas in the whole tumours obtained by Scion Image software. Data are expressed as mean±s.e. for three different tumours. n.s.: P40.05 vs
control. *Po0.05 vs control.
wwPo0.01 X-irradiated group vs combination group.
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sAs there is less X-ray-induced DNA damage in the absence of
oxygen, hypoxic cells are resistant to killing by ionising radiation
(Brown and Wilson, 2004). In addition, though severe or
prolonged hypoxia initiates apoptosis, some cells adapt to hypoxia,
survive and gain a more aggressive phenotype (Greijer and van der
Wall, 2004). These tumour cells have reduced sensitivity to
apoptosis and become more resistant to radiotherapy and
chemotherapy. Therefore, it is of interest to investigate whether
TAS106 enhances the radiation-induced apoptosis in hypoxic cells
as well as in normoxic cells.
In the present in vitro studies, TAS106 enhanced radiation-
induced apoptosis under normoxia and hypoxia in a TP53-
independent manner, although the induction rate of apoptosis
under hypoxia was smaller than that under normoxia (Figure 1B).
As shown in Figure 1C, TAS106 abrogated the X-ray-induced G2/M
checkpoint and increased the number of cells in the sub-G1
fraction under hypoxia in a fashion similar to that under
normoxia. Furthermore, the combination of X-irradiation and
TAS106 induced the activation of casapse-3 under both conditions,
suggesting a TAS106-stimulated caspase-pathway leading to
apoptosis (Figure 1D). This result supported our recent finding
that the radiosensitisation of TAS106 was cancelled by the caspase
inhibitor Z-VAD-fmk (Inanami et al, 2004). In addition, the
present experiment using UCK2 knockdown by siRNA showed that
the expression of UCK2 gene in tumour cells was responsible for
the enhancement of radiation-induced apoptosis (Figure 2B). This
result supported the previous report that a 30-ethynyl-nucleoside-
resistant cell line established from human fibrosarcoma HT-1080
had a deletion of exon 4 of UCK2 mRNA, resulting in a decrease of
UCK2 expression (Murata et al, 2004). Interestingly, the induction
of apoptosis by the combined treatment with X-irradiation and
TAS106 was also observed in hypoxic cells in MKN45 xenografts,
as shown in Figure 9. In addition to apoptosis induction, Iizuka
et al demonstrated that TAS106 enhanced the loss of clonogenic
ability by converting X-ray-induced proapoptotic cells into
apoptotic cells in Chinese hamster V79 cells (Iizuka et al, 2005).
When we examined the effect of TAS106 on clonogenic survival in
MKN45 and MKN28 cells, TAS106 enhanced radiation-induced
reproductive cell death not only normoxic condition but also
hypoxic condition (Figure 3). These findings in vitro and in vivo
strongly suggested that TAS106 could have potent activity to
enhance the radiation-induced cell death of hypoxic cells.
For the application of TAS106 for clinical use, it is important to
clarify the molecular mechanisms by which TAS106 could enhance
the apoptotic induction of tumour cells with X-irradiation. As
TAS106 is an inhibitor of RNA synthesis (Matsuda and Sasaki,
2004), we hypothesised that the expression of various apoptosis-
related proteins would be non-specifically suppressed by TAS106.
In this study, we tested the effect of TAS106 on the expression of
anti- and proapoptotic proteins, such as IAPs and Bcl-2 family, in
MKN45 cells under normoxia or hypoxia. As expected, the
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Figure 8 Suppression of HIF-1a expression by TAS106 treatment in MKN45 xenograft. Tumours were excised at 2 days after X-irradiation and/or
TAS106 administration. (A) Typical microscopic fields of MKN45 xenografts immunostained for HIF-1a.( B) Quantitative data obtained by
immunohistochemical analysis. Data are expressed as mean±s.e. for three different tumours. **Po0.01 vs control.
Bar = 50 m
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Figure 9 Induction of apoptosis in hypoxic cells of MKN45 xenografts by
the combination of TAS106 (0.5mgkg
 1) and X-irradiation (2Gy).
Tumours were excised at 2 days after X-irradiation and/or TAS106
administration. Pimonidazole-positive cells (green) and cleaved caspase-3-
positive cells (red) correspond to hypoxic cells and apoptotic cells,
respectively. Tumour cells were also counterstained with DAPI (blue).
Cleaved caspase-3-positive cells among normoxic cells (arrow head) and
hypoxic cells (merged yellow, arrow) are observed in the MKN45
xenograft treated with X-irradiation and TAS106.
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sexpressions of survivin and cIAP2 were effectively suppressed by
the treatment of TAS106 under normoxia (Figure 4B). With respect
to the role of survivin in resistance against radiation-induced
apoptosis in tumour cells under normoxia, the overexpression of
dominant-negative mutants of survivin (T34A and D53A) was
demonstrated to enhance radiation-induced apoptosis in mouse
fibroblast cell line NIH3T3, human cervical carcinoma cell line
HeLa and human lung carcinoma cell line A549 (Ogura et al, 2008).
The downregulation of both survivin mRNA and protein expres-
sion by TAS106 led to the enhancement of X-ray-induced
apoptosis and overexpression of wild-type survivin in MKN45
cells inhibited this apoptotic induction (Inanami et al, 2004).
These results indicated that survivin played an important role in
the radioresistance of tumour cells under normoxia. Interestingly,
it has been shown that the resistance of hypoxic cells to apoptosis
is modulated through the upregulation of IAPs, including survivin
and cIAP2, induced by hypoxia (Semenza, 2003). In this study, the
expression of survivin and cIAP2 was increased in MKN45 cells
under hypoxia for 24h (Figure 4A), suggesting that this upregula-
tion provided MKN45 cells with the resistance to apoptosis
observed in Figure 1B and 1C. As shown in Figure 4B, TAS106
reduced the expression of survivin and cIAP2 upregulated by
hypoxic exposure, indicating that the downregulation of these
antiapoptotic proteins by TAS106 also contributed to the
enhancement of radiation-induced apoptosis of hypoxic cells as
well as normoxia. Furthermore, we examined whether TAS106
modulated the Bcl-2 family, which is the major regulator of caspase
activation. The Upregulation of Bax and downregulation of Bcl-2
favour the proapoptotic response over the antiapoptotic one in
tumour cells, leading to the release of cytochrome c and promotion
of cell death (Cory and Adams, 2002). In this study, TAS106
treatment reduced the expression of both antiapoptotic Bcl-2 and
proapoptotic Bax proteins under both normoxia and hypoxia (data
not shown). Thus, TAS106 could not increase the Bax/Bcl-2 ratio in
MKN45 cells, suggesting that it might not make the proapoptotic
response dominant over the antiapoptotic one.
It is noteworthy that immunoblot analysis and immunohisto-
chemical analysis revealed that TAS106 treatment suppressed the
expression of HIF-1a proteins in vitro and in vivo (Figures 4C and
8). Concerning the mechanism of the HIF-1a suppression by
TAS106, semiquantitative RT–PCR showed that TAS106 inhibited
the mRNA expression of HIF-1a in MKN45 cells under hypoxia
(Figure 5A). In addition, the pattern of inhibition of HIF-1a
protein by TAS106 was similar to that of actinomycin D, a
transcription inhibitor. These results suggested that TAS106
downregulated HIF-1a expression transcriptionally as well as
actinomycin D. In addition, treatment with cycloheximide, a
protein synthesis inhibitor, also inhibits hypoxia-induced HIF-1a
expression. The adaptational response of tumour cells against
hypoxia is thought to be mainly mediated by HIF-1a, which
transactivates a number of target genes leading to metabolic
adaptation, angiogenesis, invasion/metastasis and apoptosis resis-
tance (Semenza, 2003). Recent studies reported that interfering
treatments targeting HIF-1a, such as antisense or siRNA, induced
apoptosis of human tongue squamous carcinoma cells in vitro
(Zhang et al, 2004a) and inhibited tumour growth in human
cervical and colon adenocarcinoma cells in vivo (Zhang et al,
2004b). In this experiment, we demonstrated that the reduction of
the constitutive level of HIF-1a by an antisense HIF-1a oligo-
nucleotide markedly increased the number of apoptotic cells
(Figure 6C). Zhang et al (2004a) demonstrated that the abrogation
of both basal and hypoxia-induced HIF-1a protein levels induced
apoptosis under not only hypoxia but also normoxia in squamous
carcinoma cells with constitutive HIF-1a expression. Combined
with their result, our findings suggest that maintaining a
constitutive level of HIF-1a is essential to cell survival. Interest-
ingly, we demonstrated that X-irradiation enhanced HIF-1a
reduction-induced apoptosis (Figure 6C). These data paralleled
the synergistic effect of TAS106 on X-ray-induced apoptosis as
shown in Figure 1B, suggesting that TAS106 radiosensitised cells to
apoptotic induction through the suppression of HIF-1a expression.
Recent reports have shown that survivin gene expression might be
regulated by hypoxia and subsequent activation of HIF-1a (Dong
et al, 2003; Greijer and van der Wall, 2004; Peng et al, 2006; Kilic
et al, 2007). In this experiment, survivin expression increased
under hypoxia for 24h, suggesting a linkage to hypoxia-induced
HIF-1a expression. Therefore, it is possible that the apoptotic
resistance of hypoxic cells was abrogated through the inhibition of
HIF-1a-induced antiapoptotic molecules by TAS106. Further
information is necessary to clarify the mechanism by which
TAS106 overcomes the resistance of hypoxic cells to X-ray-induced
apoptosis.
In conclusion, we demonstrated that TAS106 could radio-
sensitise apoptotic induction in not only normoxic but also
hypoxic cells in vitro and in vivo, which might be mainly related to
the inhibition of HIF-1a expression. Importantly, TAS106 sig-
nificantly reduced the hypoxic regions of X-irradiated MKN45
xenografts, probably because of this apoptotic induction. To
overcome the radioresistance of apoptosis in hypoxic cells of solid
tumours, the use of radiation sensitisers against not only normoxic
cells but also hypoxic cells is necessary in combination with
radiotherapy. On the basis of our results, the novel anticancer drug
TAS106, which was effective for hypoxic cells through HIF-1a
inhibition is a candidate sensitiser for radiotherapy.
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